BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4004913)

  • 1. Studies with 4'-deoxyepivincristine (vinepidine), a semisynthetic vinca alkaloid.
    Mullin K; Houghton PJ; Houghton JA; Horowitz ME
    Biochem Pharmacol; 1985 Jun; 34(11):1975-9. PubMed ID: 4004913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
    Houghton JA; Williams LG; Torrance PM; Houghton PJ
    Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
    Ganapathi R; Grabowski D; Schmidt H
    Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
    Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
    Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.
    Houghton JA; Houghton PJ; Hazelton BJ; Douglass EC
    Cancer Res; 1985 Jun; 45(6):2706-12. PubMed ID: 3986804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
    Pierré A; Pérez V; Léonce S; Boutin JA; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
    Cancer Chemother Pharmacol; 1992; 29(5):367-74. PubMed ID: 1551175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells.
    Gout PW; Noble RL; Bruchovsky N; Beer CT
    Int J Cancer; 1984 Aug; 34(2):245-8. PubMed ID: 6469399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
    Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
    Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
    Thimmaiah KN; Horton JK; Qian XD; Beck WT; Houghton JA; Houghton PJ
    Cancer Commun; 1990; 2(7):249-59. PubMed ID: 2378785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study.
    Lengsfeld AM; Dietrich J; Schultze-Maurer B
    Cancer Res; 1982 Sep; 42(9):3798-805. PubMed ID: 7105045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities - part I.
    Dubrovay Z; Háda V; Béni Z; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():293-308. PubMed ID: 22985529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.
    Zhou XJ; Martin M; Placidi M; Cano JP; Rahmani R
    Eur J Drug Metab Pharmacokinet; 1990; 15(4):323-32. PubMed ID: 2088769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components.
    Iqbal Z; Ochs S
    J Neurochem; 1980 Jan; 34(1):59-68. PubMed ID: 6161213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
    Horton JK; Houghton PJ; Houghton JA
    Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Block of axoplasmic transport in vitro by vinca alkaloids.
    Chan SY; Worth R; Ochs S
    J Neurobiol; 1980 May; 11(3):251-64. PubMed ID: 6156229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activities of harringtonine and homoharringtonine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration.
    Takeda S; Yajima N; Kitazato K; Unemi N
    J Pharmacobiodyn; 1982 Oct; 5(10):841-7. PubMed ID: 7161711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA; Himes RH; Wilson L
    Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
    Pierré A; Lavielle G; Hautefaye P; Seurre G; Leonce S; Saint-Dizier D; Boutin JA; Cudennec CA
    Anticancer Res; 1990; 10(1):139-44. PubMed ID: 2334119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.
    Houghton JA; Houghton PJ; Brodeur GM; Green AA
    Int J Cancer; 1981 Oct; 28(4):409-15. PubMed ID: 7309287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.